Retrospective Study
Copyright ©The Author(s) 2018.
World J Clin Cases. Oct 26, 2018; 6(12): 521-530
Published online Oct 26, 2018. doi: 10.12998/wjcc.v6.i12.521
Table 1 Baseline characteristics of the subjects
CharacteristicsTotal group(n = 599)ALT ≤ 40 group (n = 272)40 < ALT ≤ 80group (n = 190)ALT > 80 group(n = 137)P-value
Age (yr)37 (29, 44)39 (31.25, 46)37.5 (28, 43.25)34 (28, 40.5)< 0.001
Male (%)349 (58.3)131 (48.2)130 (68.4)88 (64.2)< 0.001
ALT (U/L)44 (28, 76)26 (31, 33)56 (48, 66)127 (95, 218.5)< 0.001
AST (U/L)32 (24, 48)24 (20, 28)36 (31, 42)70 (55, 115.5)< 0.001
GGT (U/L)25 (17, 41)19 (14, 25)30 (20, 41.25)48 (30, 78)< 0.001
Cholesterol (mmol/L)4.31 (3.84, 4.96)4.35 (3.86, 4.95)4.24 (3.75, 4.95)4.34 (3.84, 4.99)0.732
PLT (109/L)182 (150, 217)184 (155, 223)177.5 (145.5, 212)180 (149, 215)0.215
INR1 (1, 1.1)1 (1, 1.1)1 (0.99, 1.1)1 (0.94, 1.1)0.4
HBV DNA (log10IU/mL)7.03 (4.24, 8.23)4.77 (3.32, 7.78)7.64 (5.72, 8.23)8.03 (6.81, 8.23)< 0.001
S (%)
S0264 (44.1)128 (47.1)80 (42.1)56 (40.9)
S1147 (24.5)73 (26.8)53 (27.9)21 (15.3)
S296 (16)35 (12.9)29 (15.3)32 (23.4)
S354 (9)19 (7.0)18 (9.5)17 (12.4)
S438 (6.3)17 (6.3)10 (5.3)11 (8.0)
Stage S0-1 fibrosis411 (68.6)201 (73.9)133 (70)77 (56.2)0.001
Stage S2-4 fibrosis188 (31.4)71 (26.1)57 (30)60 (43.8)
APRI0.53 (0.38,0.86)0.38 (0.3, 0.49)0.61 (0.44,0.8)1.16 (0.88, 1.93)< 0.001
FIB-41.02 (0.72,1.47)1.02 (0.72,1.37)0.96 (0.66,1.55)1.22 (0.82, 1.79)< 0.001
GPR0.22 (0.15,0.38)0.16 (0.11, 0.23)0.24 (0.17,0.38)0.42 (0.25, 0.68)< 0.001
King’s score6.77 (4.31,11.49)4.89 (3.54,7.03)7.18 (4.58,11.58)13.04 (9.81, 27.15)< 0.001
Forns index6.48 (5.44,7.51)6.33 (5.37,7.37)6.57 (5.51,7.69)6.65 (5.57, 7.57)0.081